Trial Profile
Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 May 2023
Price :
$35
*
At a glance
- Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2023 Interim Results assessing efficacy and safety of Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma published in the Leukemia
- 13 Dec 2022 Results of sub-analysis evaluating the role of adding Romidepsin to CHOEP followed by high dose chemotherapy and SCT in newly diagnosis AITL and T-helper follicular lymphoma patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Primary endpoint has not been met. (Progression Free Survival (PFS) of Ro-CHOEP-21 (Phase II endpoint))as per Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition